Novo Nordisk Hopes To Gradually Build US Access To Obesity Therapy
With US FDA approval of Wegovy for obesity, Novo Nordisk prices the weekly injectable at par with its other obesity brand Saxenda. Ramping up sales will require patient, clinician and payer education, the company says.
You may also be interested in...
Tirzepatide shows ability to produce a mean 52-pound weight loss at 72 weeks, setting up a market showdown with Novo’s Wegovy. Lilly’s quarterly call included reassurance about donanemab for Alzheimer’s and high growth for its COVID-19 antibody.
The company is targeting revenues of DKK25bn ($3.66bn) from Wegovy for obesity in 2025, with plans to amp up the US launch this year following an initial supply disruption.
The failed muscle-adding antibody could offer a superior profile in obesity by reducing body fat composition while increasing lean mass, the firm believes.